<DOC>
	<DOCNO>NCT00547131</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . Collecting fluid sample catheter may help doctor find well temozolomide spread throughout brain . PURPOSE : This clinical trial study temozolomide treat patient primary brain tumor metastatic brain tumor .</brief_summary>
	<brief_title>Temozolomide Treating Patients With Primary Brain Tumors Metastatic Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility microdialysis assess intracerebral distribution temozolomide patient primary metastatic brain tumor . - Determine interstitial pharmacokinetics temozolomide use intracerebral microdialysis catheter patient . - Determine feasibility assess brain tumor metabolism use microdialysis catheter measure intracerebral level glucose , lactate , pyruvate , glutamate , glycerol patient . OUTLINE : Patients assess viable tumor debulking craniotomy stereotactic biopsy . If viable tumor confirm , patient undergo placement intracerebral microdialysis ( MD ) catheter . The catheter , perfuse continuously 24 hour artificial cerebrospinal fluid , place directly residual brain tumor peritumoral brain tissue neuropharmacokinetic study temozolomide . At least 25 hour 72 hour placement catheter , patient receive single dose oral temozolomide . At time , intracerebral MD initiate serial sample dialysate ( i.e. , brain extracellular fluid [ ECF ] ) collect periodically 24 hour analysis intracerebral concentration temozolomide liquid chromatography/tandem mass spectrometry . Serial blood sample measure plasma level temozolomide also draw plasma temozolomide level compare brain ECF . Additional ECF sample obtain assess biochemical marker brain tumor metabolism ( i.e. , glucose , lactate , pyruvate , glutamate , glycerol ) least one hour 24 hour administration temozolomide . After completion study therapy , patient follow 30 day .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis primary metastatic brain tumor temozolomide would appropriate chemotherapy treatment postoperatively Disease require debulking craniotomy stereotactic biopsy diagnose differentiate tumor progression treatmentinduced effect radiotherapy without chemotherapy PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin ≤ 2.0 mg/dL AST ≤ 4 time upper limit normal ( ULN ) Creatinine ≤ 1.5 time ULN Mini Mental Status Exam score ≥ 15 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No allergy temozolomide No serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion study treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy No concurrent chemotherapy radiotherapy period time microdialysis catheter place intracerebrally remove</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>tumor metastatic brain</keyword>
	<keyword>recurrent adult brain tumor</keyword>
</DOC>